Pharmacology > Slide Presentations

No Title Presenter Date
84 [TCTAP A-093] Determinants of Self-Discontinuation of Secondary Prevention Medications by Coronary Heart Disease Outpatients: Focus on the Role of Erectile Dysfunction Muhamad Ali SK Abdul Kader Apr. 20. 15
83 [TCTAP A-001] Outcomes of 6 Months Versus 12 Months Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Biolimus or Durable Polymer Zotarolimus-Eluting Stents: OPTIMA-C Study and Optical Coherence Tomography Sub-Study Byoung Kwon Lee Apr. 20. 15
82 The Role of Triple Antiplatelet Therapy in Patients with High Risk Young-Hoon Jeong Jul. 22. 09
81 Tailoring Treatment to Risk in Antiplatelet Therapy Alexandra J. Lansky Jul. 22. 09
80 What Is the Optimal Duration of DAPT Following DES Treatment? David E. Kandzari Jul. 22. 09
79 Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib Roxana Mehran Jul. 22. 09
78 Strategic Approaches to Obtain Better and Earlier CV Outcome Weon Kim Jul. 22. 09
77 Does the Efficacy of Bivalirudin During PCI Depend on Clopidogrel Pretreatment? Matthew Price Jul. 22. 09
76 STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel) Gregg W. Stone Jul. 22. 09
75 Systemic Therapy for Plaque Stabilization: New Drugs Targeting LP-PLA2 Patrick W. Serruys Jul. 22. 09
74 New Paradigms in Treatment of ACS/AMI Roxana Mehran Jul. 22. 09
73 The Role of Triple Antiplatelet Therapy in Patients with High Risk Young-Hoon Jeong May. 13. 09
72 Tailoring Treatment to Risk in Antiplatelet Therapy Alexandra J. Lansky May. 13. 09
71 Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice? David J. Cohen May. 13. 09
70 What Is the Optimal Duration of Dual Antiplatelet Therapy Following DES Treatment? David E. Kandzari May. 13. 09
CardioVascular Research Foundation (CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea
Tel_82.2.3010.4792 | Fax_82.2.475.6898
재단법인 심장혈관연구재단
대표이사 박승정 | 서울시 송파구 올림픽로43길 88, 서울아산병원 아산교육연구관 2층 | 사업자등록번호 215-82-06387
개인정보 관리책임자_노순정 | 전화번호_02.3010.4792 | 팩스번호_02.475.6898
Copyright © CVRF, Seoul, Korea. All rights reserved.